DNA plasmids News
-
CD Genomics Introduces Complete Plasmid DNA Sequencing Service Accelerating Genetic Research
CD Genomics, a globally recognized leader in genomics services, has recently unveiled its Complete Plasmid DNA Sequencing service, empowering researchers with cutting-edge solutions for genetic exploration. This service aims to provide scientists in various fields, such as molecular biology, genetics, and gene engineering, with exceptional support, enabling them to gain comprehensive insights ...
By CD Genomics
-
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive ...
-
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
Enables gene therapy clients to accelerate AAV manufacturing with seamless incorporation into the Company’s HEK 293 platform suspension process with access to end-to-end capabilities New offerings of Research-Grade and GMP-Pathway expedite Phase 1/2 clinical trial timelines, with GMP-Grade available in 2023 Data to support Company’s plasmid production is being presented at ...
-
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, as the saRNA molecule encodes a viral RNA replicase in addition to the sequence of the protein(s) of interest. This mechanism leads to enhanced and prolonged protein ...
-
Thermo Fisher Expands Clinical and Commercial Capabilities for Plasmid DNA Manufacturing
Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. The site will expand the company's clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments as well as ...
-
Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in ...
By Eyevensys
-
Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases
Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Dr. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the novel technology during the Gene & Cell Therapy Spotlight session. The company’s ...
By Eyevensys
-
Eyevensys Named to French Tech 120 Program
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021. This government-backed program, run by La French Tech, offers support for 120 French startups considered late-stage and in a hypergrowth phase. Participating companies benefit from a variety ...
By Eyevensys
-
Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted an orphan-drug designation (ODD) for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit ...
By Eyevensys
-
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial ...
-
Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Eyevensys has developed a non-viral gene therapy ocular ...
By Eyevensys
-
INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern. Concurrently, INOVIO ...
-
Expanded Gene Therapy Portfolio Supports More Efficient Adeno-Associated Viral Manufacturing
For gene therapy developers seeking to rapidly and efficiently scale production, a set of solutions is now available from Thermo Fisher Scientific to support adeno-associated viral (AAV) manufacturing. A new media panel, gene kit and advanced purification resins help reduce manufacturing costs while increasing the viability of gene therapies as treatment options for patients. AAV is a ...
-
Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The conference will be held May 1-4, ...
By Eyevensys
-
INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, announced today that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference (IPVC) , which is being held virtually from today, ...
-
Creative Enzymes Unveils the Creative SuperCut Series: Redefining Precision in Molecular Biology
Creative Enzymes, a pioneering force in the field of biotechnology, has once again raised the bar in molecular biology with the launch of its Creative SuperCut Series. This breakthrough product line is designed to revolutionize the way scientists approach restriction enzyme digests, making it faster and more efficient than ever before. Creative Enzymes’ Creative SuperCut Series is ...
-
Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606 for Non-Infectious Uveitis (NIU). The patient was treated in Paris, France at the Cochin Institute by Professor Antoine Brézin, the principal investigator of the trial, using the company’s novel EyeCET technology. EYS606 is the ...
By Eyevensys
-
CHA Medical & Bio Group Announces Groundbreaking for Its New Cell Gene Biobank Facility
CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new 710,000 ft2 site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be ...
-
Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer
Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive global sales and new business growth. ...
-
Eyevensys Announces Executive Leadership Team Expansion
Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the expansion of its leadership team with the appointment of Gerald Cagle as the ...
By Eyevensys
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you